Amicus’ Pompe disease therapy joins early access scheme
The MHRA has issued an EAMS scientific opinion opening the door to use of cipaglucosidase alfa with miglustat in eligible patients with Pompe disease
Read Moreby Selina McKee | Jun 9, 2021 | News | 0
The MHRA has issued an EAMS scientific opinion opening the door to use of cipaglucosidase alfa with miglustat in eligible patients with Pompe disease
Read Moreby Selina McKee | Dec 17, 2018 | News | 0
The European Medicines Agency’s human medicines committee (CHMP) has put forward seven medicines for approval in the region.
Read Moreby Selina McKee | Sep 18, 2017 | News | 0
Thirteen new therapies – including two biosimilars – have been backed for approval in Europe.
Read Moreby Selina McKee | Jan 30, 2017 | News | 0
Eight medicines – including two biosimilars – have taken a giant step towards being approved for the European market having won favour with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
